Release Date: May 29, 2007
Valid Through: May 28, 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM

Fee: There is no fee for this activity

This CME activity is based on the following:

New Agents for the Treatment of Lymphomas: A Review of the Literature
Author: Fredrick B. Hagemeister, MD, The Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

With Comments by: John P. Leonard, MD, Associate professor of Medicine, Weill Medical College of Cornell University; clinical director, New York-Cornell Center for Lymphoma and Myeloma in New York City

Fredrick B. Hagemeister, M.D., is an internist and Professor of Medicine as well as Chief of the Department of Lymphoma/Myeloma at the University of Texas M. D. Anderson Cancer Center. He is an active member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Society of Hematology.  He has lectured at the Medical Oncology Fellow Weekly Lecture on the management of late stage Hodgkin’s disease and for the Non-Hodgkin’s Advisory Board on the use of interferon in low-grade lymphomas. He has also served as the editor of a management of lymphoma series entitled “Nursing Counseling Challenges” for the Medical Age Publishing Company.

Other research interests of Dr. Hagemeister include the pathology of the lymphomas, the management of early stage Hodgkin’s disease, chemotherapy for large cell lymphoma of the stomach, and the outcome of Hodgkin’s disease in the elderly.  Recent publications include articles in Leukemia and Lymphomas, Biomedicine & Pharmacotherapy, and in Blood.  In addition, Dr. Hagemeister has authored a chapter on the management of relapsing Hodgkin’s disease in Hodgkin’s Disease and Non-Hodgkin’s Lymphomas in Adults and Children (Raven Press).  He has also co-authored chapters on the treatment of laparotomy-stage I and II Hodgkin’s disease, and bone marrow transplantation in lymphoma for the Anderson Clinical Conference on Cancer (Raven Press).

Dr. Hagemeister received his medical degree from the University of Texas Southwestern Medical School in Dallas, Texas, where he also completed a fellowship in oncology.  His internship and residency were served at Charity Hospital in New Orleans.

John P. Leonard, MD

John P. Leonard, M.D., is Associate Professor of Medicine at the Weill Medical College of Cornell University. He also serves as Clinical Director at the New York – Cornell Center for Lymphoma and Myeloma.  In addition, he is associate attending physician at the New York – Weill Cornell Center of New York Presbyterian Hospital and serves as Director of Clinical Research in the Division of Hematology/Oncology.  An expert in hematology and oncology, Dr. Leonard’s research has been published in numerous medical journals, and he has served as a member of the editorial boards of Blood and the Journal of Clinical Oncology.  He serves as the non-Hodgkin’s lymphoma working group leader for the Lymphoma Committee of the Cancer and Leukemia Group B (CALGB), a multicenter cooperative group of the National Cancer Institute.  His primary research interest is in the development of novel therapeutic strategies for the treatment of hematologic malignancies.  Much of his work has involved the development of radiolabeled and unlabeled monoclonal antibodies as therapy for lymphoma, vaccine and other immune-based treatments, and other novel therapeutic approaches.  Dr. Leonard performed his undergraduate work at Johns Hopkins University and received his medical degree at the University of Virginia School of Medicine in Charlottesville, VA.  He completed his residency in medicine at the New York Hospital - Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York, NY.  He completed a fellowship in hematology and oncology at Cornell, and served as the Chief Medical Resident at the New York Hospital, Cornell Medical Center.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Identify monoclonal antibodies that are currently being evaluated in clinical trials for relapsed lymphomas and consider phase I/II studies of galiximab and epratuzumab for lymphomas.
• Define targeted inhibitors that are being evaluated in lymphoma therapies.
• Consider aminopterin derivatives, their mechanism of action and bioavailability as well as response rates for T-cell lymphomas in recent clinical trials.
• Consider ongoing clinical trials evaluating bortezomib in lymphomas and understand the pivotal trial that led to the FDA approval of bortezomib in the management of relapsed mantel cell lymphoma.
• Identify other agents that are being evaluated in clinical trials for the management of lymphomas.
  

Disclaimer
Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters
This activity is supported by an unrestricted educational grant from Bayer HealthCare Pharmaceuticals.

Release Date: March 30, 2007

Valid Through: March 29, 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM



Fee: There is no fee for this activity

This CME activity is based on the following original interactive case study:

Review of the Literature Regarding Treatment for Head and Neck Cancer: Six Articles with the Most Clinical Significance Published in the Last Two Years

Marshall R. Posner, MD, Medical Director, Head and Neck Oncology Program, Dana-Farber Cancer Institute

With Comments by David Raben, MD, University of Colorado Health Sciences Center

Dr. Marshall Posner is the Medical Director of the Head and Neck Oncology Program at the Dana-Farber Cancer Institute, one of the first multi-disciplinary head and neck cancer programs established in this country. Dr. Posner graduated in 1971 from Yale University and received his MD from Tufts University School of Medicine in 1975. He completed a residency in Internal Medicine at Boston City Hospital in 1978 and became a fellow in Medical Oncology at the Dana-Farber Cancer Institute. He completed his fellowship in 1981 and became an Instructor in Medicine. He was a member of the multi-disciplinary head and neck clinic at the Dana-Farber Cancer Institute from 1979-1983 and a member of the Division of Tumor Immunology. In 1983 Dr. Posner joined the Roger Williams Cancer Center and the Brown University Medical School as an Assistant Professor where he helped develop a Phase II clinical trials program and established the Human Monoclonal Antibody Laboratory. In 1991 Dr. Posner joined the New England Deaconess Hospital and in 1994 was appointed the Medical Director of the Head and Neck Oncology Program at DFCI. He became an associate Professor of Medicine at Harvard Medical School in 1994. Dr. Posner has published over 140 peer reviewed basic laboratory and clinical studies as well as numerous reviews and abstracts in clinical research and basic laboratory studies.

David Raben, MD

David Raben, MD, is an Associate Professor and Associate Scientist in the Department of Radiation Oncology at the University Colorado Comprehensive Cancer Center, Aurora, Colorado. Dr. Raben received his medical degree from the Bowman Gray School of Medicine, Wake Forest University, Winston Salem, North Carolina, and completed his residency in Radiation Oncology at Johns Hopkins University, Baltimore, Maryland. At present he is an associate scientist and associate professor in the Department of Radiation Oncology at the University of Colorado Cancer Center. Dr. Raben has established himself in the area of translational research combining radiation with biologic agents that alter the cancer cell growth cycle to enhance the effectiveness of radiation therapy for head and neck cancer.  Dr. Raben is board certified, active member of the American College of Radiology, American Society for Therapeutic Radiology and Oncology, American Society of Clinical Oncology and the American Association of Cancer Research.  Dr. Raben serves on the Translational Research Committee of the Radiation Therapy Oncology Group, American Society for Therapeutic Radiology and Oncology (ASTRO) Educational Committee, ASCO publications committee, the Southwest Oncology Group Radiation Oncology Committee and University of Colorado Cancer Committee. He also participates in the Young Leadership committee of ASTRO. He has been a participating or lead author in 42 published articles and is an adhoc reviewer for the American Journal of Clinical Oncology, Clinical Cancer Research, International Journal of Radiation Oncology Biology Physics, British Journal of Cancer, and Head and Neck.  He is currently on the editorial board of the JCO, Signal and International Journal of Cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss the most clinically significant published articles from the last 2 years regarding the treatment of head and neck cancer (HNC)
• Evaluate the pathologic predictors of poor prognosis in completely resected HNC
• Consider the chemotherapeutic drug options to use with radiotherapy in the post-operative setting
• Consider Phase III data and side effect profile of emerging biologic therapy in combination with radiation therapy for locally advanced HNC

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb Company.